

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

NCT07368478

Status	RECRUITING
Phase	Phase 1
Sponsor	Biocity Biopharmaceutics Co., Ltd.
Enrollment	180 participants

Key Eligibility Criteria

Inclusion (42)

- Provide written informed consent.
- Be at least 18 years old.
- Have an Eastern Cooperative Group (ECOG) performance status (PS) of 0 or 1.
- Have a life-expectancy of at least 3 months based on the Investigator's assessment.
- Patients with advanced solid tumors confirmed by histology or cytology, who have failed standard therapy, have no available standard therapy, or are intolerant to standard therapy.

... and 37 more (see full listing online)

Exclusion (20)

- Prior treatment with GPC3-targeted ADC.
- Prior treatment with systemic anticancer treatment, including investigational agents, within a period that is less than five half-lives or 2 weeks before the start of treatment, whichever is shorter.
- Known hypersensitivity or delayed hypersensitivity reactions to the same class and/or any component of BC2027.
- Treatment with strong CYP3A4 inhibitors or inducers, and P-gp inhibitors within 14 days or 5 half-lives whichever is shorter, before the first dose.
- For patients with advanced NSCLC:

... and 15 more (see full listing online)

Locations (1 total)

Shanghai Chest Hospital, Shanghai, Shanghai, China, China